Akero Therapeutics Inc. (AKRO)
Akero Therapeutics Statistics
Share Statistics
Akero Therapeutics has 79.62M shares outstanding. The number of shares has increased by 1.24% in one year.
| Shares Outstanding | 79.62M |
| Shares Change (YoY) | 1.24% |
| Shares Change (QoQ) | 0.53% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 70.68M |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 3.35M, so 4.8% of the outstanding shares have been sold short.
| Short Interest | 3.35M |
| Short % of Shares Out | 4.8% |
| Short % of Float | 5.74% |
| Short Ratio (days to cover) | 4.23 |
Valuation Ratios
The PE ratio is -7.41 and the forward PE ratio is -10.69. Akero Therapeutics's PEG ratio is -0.25.
| PE Ratio | -7.41 |
| Forward PE | -10.69 |
| PS Ratio | 0 |
| Forward PS | 10.2 |
| PB Ratio | 2.49 |
| P/FCF Ratio | -8.12 |
| PEG Ratio | -0.25 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Akero Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.38, with a Debt / Equity ratio of 0.
| Current Ratio | 19.38 |
| Quick Ratio | 19.38 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.07 |
| Cash Flow / Debt | -434.98 |
| Interest Coverage | 61.14 |
Financial Efficiency
Return on equity (ROE) is -0.34% and return on capital (ROIC) is -38.02%.
| Return on Equity (ROE) | -0.34% |
| Return on Assets (ROA) | -0.31% |
| Return on Capital (ROIC) | -38.02% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-4,000,952.38 |
| Employee Count | 63 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 77.34% in the last 52 weeks. The beta is -0.2, so Akero Therapeutics's price volatility has been lower than the market average.
| Beta | -0.2 |
| 52-Week Price Change | 77.34% |
| 50-Day Moving Average | 44.64 |
| 200-Day Moving Average | 31.86 |
| Relative Strength Index (RSI) | 44.3 |
| Average Volume (20 Days) | 1.35M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -285.42M |
| Net Income | -252.06M |
| EBITDA | -285.42M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -3.75 |
Balance Sheet
The company has 340.24M in cash and 529K in debt, giving a net cash position of 339.71M.
| Cash & Cash Equivalents | 340.24M |
| Total Debt | 529K |
| Net Cash | 339.71M |
| Retained Earnings | -826.16M |
| Total Assets | 825.89M |
| Working Capital | 730.63M |
Cash Flow
In the last 12 months, operating cash flow was -230.11M and capital expenditures 0, giving a free cash flow of -230.11M.
| Operating Cash Flow | -230.11M |
| Capital Expenditures | 0 |
| Free Cash Flow | -230.11M |
| FCF Per Share | -3.43 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AKRO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -8.65% |
| FCF Yield | -6.67% |
Analyst Forecast
The average price target for AKRO is $75, which is 73% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $75 |
| Price Target Difference | 73% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | 27.09 |
| Piotroski F-Score | 1 |